Prof. Dr. Gherardo Mazziotti, MD,
PhD, works as a Head of Metabolic Bone Diseases and Osteoporosis Section at IRCCS Humanitas Research Hospital (Rozzano, Italy)
and is affiliated with Humanitas University (Pieve Emanuele, Italy) as an Associate
Professor of Endocrinology (Department of Medical Sciences). Prof. Dr. Mazziotti
has a PhD in General Pathology from the University of Campania Luigi Vanvitelli in 2004 and a post-doctoral PhD in GH and bone at University of
Brescia in 2005. Prof. Dr. Mazziotti has carried
out seminal studies in the field of bone and mineral metabolism, contributing to the understanding of the mechanisms and clinical
presentation of skeletal fragility induced by endocrine diseases and
therapies in oncological patients. His two main accomplishments included the first application of
vertebral morphometry for the diagnosis of skeletal fragility in patients with
osteoporosis related to endocrine disease and the demonstration in humans that
pituitary hormones (i.e., thyrotropin and prolactin) may have direct effects on
bone and may directly influence skeletal fragility. He was
also a lead author of studies on glucocorticoid-induced osteoporosis and
multi-center studies in oncology investigating the management of bone
metastases from thyroid cancer and the efficacy and safety of non-conventional
therapeutic schedules in acromegaly.
Prof. Dr. Gherardo Mazziotti, MD,
PhD, works as a Head of Metabolic Bone Diseases and Osteoporosis Section at IRCCS Humanitas Research Hospital (Rozzano, Italy)
and is affiliated with Humanitas University (Pieve Emanuele, Italy) as an Associate
Professor of Endocrinology (Department of Medical Sciences). Prof. Dr. Mazziotti
has a PhD in General Pathology from the University of Campania Luigi Vanvitelli in 2004 and a post-doctoral PhD in GH and bone at University of
Brescia in 2005. Prof. Dr. Mazziotti has carried
out seminal studies in the field of bone and mineral metabolism, contributing to the understanding of the mechanisms and clinical
presentation of skeletal fragility induced by endocrine diseases and
therapies in oncological patients. His two main accomplishments included the first application of
vertebral morphometry for the diagnosis of skeletal fragility in patients with
osteoporosis related to endocrine disease and the demonstration in humans that
pituitary hormones (i.e., thyrotropin and prolactin) may have direct effects on
bone and may directly influence skeletal fragility. He was
also a lead author of studies on glucocorticoid-induced osteoporosis and
multi-center studies in oncology investigating the management of bone
metastases from thyroid cancer and the efficacy and safety of non-conventional
therapeutic schedules in acromegaly.